The article from Courage Against Cancer emphasizes the importance of critically evaluating cancer treatment claims, particularly viral studies like the 2026 Hulscher et al. ivermectin-mebendazole paper. It provides a structured framework for assessing study validity, distinguishing between preclinical and clinical evidence, and understanding potential conflicts of interest to make informed treatment decisions.
How Cancer Patients and Caregivers Should Evaluate Viral Claims About Unproven Treatments
